eligibility_summary
Eligible: >=18, untreated CD20+ FL grade 1-3A (no transformation), treatment-needed per modified GELF, ECOG 0-2, adequate labs/organ function, consent, tumor sample, contraception. Exclude: urgent cytoreduction, stage I/curative RT, significant immunosuppression, active HBV/HCV/HIV/COVID, major cardiac or QTcF>470, CNS lymphoma, autoimmune/HLH, transplant, pregnancy, anti-CD20 allergy, recent surgery/CAR-T/other therapy, live vaccines, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in untreated CD20+ follicular lymphoma testing two immunotherapies: 1) Epcoritamab (DuoBody-CD3xCD20, subcutaneous T-cell–redirecting bispecific antibody). Mechanism: binds CD3 on T cells and CD20 on B cells to bring them into proximity, activating T-cell cytotoxicity to lyse lymphoma cells. 2) Rituximab (IV chimeric anti‑CD20 monoclonal antibody). Mechanism: targets CD20 on B cells, inducing immune-mediated killing via ADCC and complement-dependent cytotoxicity, leading to B-cell depletion. Targets/cells/pathways: CD20+ malignant B cells, CD3+ T cells, T-cell effector cytotoxic pathways, Fc-mediated ADCC (NK/macrophages) and complement cascade. Purpose: enhance immune-mediated clearance of FL in the first-line setting.